- Home
- AMLX vs CDXC Comparison
AMLX vs CDXC Comparison
Compare AMLX & CDXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMLX
- CDXC
- Stock Information
- Founded
- AMLX 2014
- CDXC 1999
- Country
- AMLX United States
- CDXC United States
- Employees
- AMLX N/A
- CDXC N/A
- Industry
- AMLX Biotechnology: Pharmaceutical Preparations
- CDXC Medicinal Chemicals and Botanical Products
- Sector
- AMLX Health Care
- CDXC Health Care
- Exchange
- AMLX Nasdaq
- CDXC Nasdaq
- Market Cap
- AMLX 481.9M
- CDXC 546.9M
- IPO Year
- AMLX 2022
- CDXC N/A
- Fundamental
- Price
- AMLX $4.76
- CDXC $6.82
- Analyst Decision
- AMLX Buy
- CDXC Strong Buy
- Analyst Count
- AMLX 7
- CDXC 2
- Target Price
- AMLX $6.00
- CDXC $8.00
- AVG Volume (30 Days)
- AMLX 1.7M
- CDXC 2.8M
- Earning Date
- AMLX 11-07-2024
- CDXC 10-31-2024
- Dividend Yield
- AMLX N/A
- CDXC N/A
- EPS Growth
- AMLX N/A
- CDXC N/A
- EPS
- AMLX N/A
- CDXC 0.02
- Revenue
- AMLX $196,485,000.00
- CDXC $91,668,000.00
- Revenue This Year
- AMLX N/A
- CDXC $18.64
- Revenue Next Year
- AMLX $149.49
- CDXC $20.72
- P/E Ratio
- AMLX N/A
- CDXC $351.56
- Revenue Growth
- AMLX N/A
- CDXC 9.95
- 52 Week Low
- AMLX $1.58
- CDXC $1.32
- 52 Week High
- AMLX $19.95
- CDXC $7.58
- Technical
- Relative Strength Index (RSI)
- AMLX 45.23
- CDXC 70.03
- Support Level
- AMLX $4.88
- CDXC $6.22
- Resistance Level
- AMLX $7.27
- CDXC $7.58
- Average True Range (ATR)
- AMLX 0.59
- CDXC 0.63
- MACD
- AMLX -0.18
- CDXC 0.17
- Stochastic Oscillator
- AMLX 7.03
- CDXC 81.42
About AMLX Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder.
About CDXC ChromaDex Corporation
ChromaDex Corp is a bioscience company dedicated to healthy aging. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen. The company has three reportable segments namely Consumer Products, Ingredients segment, and Analytical Reference Standards and Services. The majority of the revenue is earned from the Consumer Products segment.